0B68 Mitchell, Edith P. - Thomas Jefferson University - Thomas Jefferson University
Dr. Mitchell

Edith P. Mitchell, MD, FACP

Contact Dr. Mitchell

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874
(215) 503-9506 fax

Most Recent Peer-reviewed Publications

  1. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
  2. Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer
  3. Targeted Therapy for Metastatic Colorectal Cancer: Role of Aflibercept
  4. A Randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard)
  5. Mucinous colloid carcinoma of the colon metastatic to the breast
  6. Radiation therapy oncology group 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer
  7. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
  8. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan 1558 in second-line therapy for metastatic colorectal cancer: The secondary analysis from STEPP (skin toxicity evaluation protocol with panitumumab) by KRAS status
  9. Gastric cancer
  10. Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy?
  11. The Influence of Prognostic Factors and Adjuvant Chemoradiation on Survival After Pancreaticoduodenectomy for Ampullary Carcinoma
  12. Management of hypersplenism by partial splenic embolization with ethylene vinyl alcohol copolymer
  13. Reply to M. Rother
  14. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers
  15. Long term survival after colonic stenting and restenting for malignant colonic obstruction
  16. Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer
  17. Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer
  18. Does diabetes mellitus influence pathologic complete response and tumor downstaging after neoadjuvant chemoradiation for esophageal and gastroesophageal cancer? A two-institution report
  19. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group
  20. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
0